UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors

    • Categories

    Archives

    Jul

    10

    Helen Tarleton Recognized as a Working for Cures Employee Champion

    Read More Share:linkedin| twitter| email

    Jun

    24

    FINTEPLA® (fenfluramine) Results Examining its Impact in Managing Generalized Tonic-Clonic Seizures in Developmental and Epileptic Encephalopathies Published in Epilepsia

    Read More Share:linkedin| twitter| email

    Jun

    20

    UCB Launches Dravet Syndrome Sound of Profound Moments: Family Video Project

    Read More Share:linkedin| twitter| email

    Jun

    13

    UCB at EULAR 2024: Advancing Science for Rheumatic Conditions with High Unmet Needs

    Read More Share:linkedin| twitter| email

    Jun

    13

    New CIMZIA® data for women living with chronic rheumatic diseases throughout pregnancy, and for people living with RA and high rheumatoid factor levels

    Read More Share:linkedin| twitter| email

    Jun

    12

    UCB to share first presentations of BIMZELX® (bimekizumab-bkzx) two-year data in axial spondyloarthritis and psoriatic arthritis at EULAR 2024

    Read More Share:linkedin| twitter| email

    Jun

    10

    Nicole Watson: Mom, Caregiver, and Best Friend, Shares How Her Daughter Emma, Diagnosed with Dravet Syndrome, Embraces Each Day with Love

    Read More Share:linkedin| twitter| email

    May

    31

    Go Behind The Mystery of Myasthenia Gravis On Myasthenia Gravis Awareness Month

    Read More Share:linkedin| twitter| email

    May

    31

    Empowering the Hidradenitis Suppurativa Community: UCB's Triple Approach

    Read More Share:linkedin| twitter| email

    May

    23

    UCB Announces Publication in The Lancet of Phase 3 BIMZELX® (bimekizumab-bkzx) Trials in Moderate-to-Severe Hidradenitis Suppurativa

    Read More Share:linkedin| twitter| email

    © 2009 - 2020 UCB, Inc., Atlanta. All rights reserved.
    USPR-CORP-0115-00003(2)